Annual report pursuant to Section 13 and 15(d)

Long-Term Debt and Other Financings (Tables)

v3.20.4
Long-Term Debt and Other Financings (Tables)
12 Months Ended
Dec. 31, 2020
Long-Term Debt and Other Financings  
Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt

Aggregate future principal, final payment fees and discounts of the Company’s long-term debt as of December 31, 2020, are as follows (in thousands):

December 31, 

2020

2021

$

8,533

2022

13,523

Thereafter

Total payments

22,056

Less: interest, final payment fees, discount and issuance costs

(1,204)

Total payments, net of interest, final payment fees, discount and issuance costs

20,852

Less: current portion of long-term debt

(8,088)

Long-term debt

 

$

12,764

Interest Expense and Amortization of Debt Issuance Costs and Discounts

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2020 and 2019, relates to the following debt instruments (in thousands):

Year Ended December 31, 

    

2020

    

2019

SVB loan

$

1,365

$

1,207

Novartis note

 

477

 

706

Other

 

2

 

6

Total interest expense

$

1,844

$

1,919